Stock Analysis of aTyr Pharma Inc (LIFE) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code LIFE
Close 2.00
Change 0.070 / 3.63 %
Volume 577188
Vol Change 154127 / 36.43 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of aTyr Pharma Inc
PE (TTM)

-512.96

Very Poor
Price / Book

282.71

Very Poor
Price / Sales

5642.09

Very Poor
Piotroski F Score

4.0

Indecisive
Market Cap

138021 K

Enterprise Value

116805 K

ROA (TTM)

-42.90

Very Poor
ROE (TTM)

-55.09

Very Poor
Net Margin (TTM)

-1099.92

Very Poor
Revenue

3.40 %

10739.00 K
Net Profit

4.83 %

-43150.00 K
Debt to Equity

0.0146

Excellent
Altman Z Score

-2.89

Very Poor
Quick Ratio

11.03

Excellent
Cash Ratio

1.37

Indecisive


Highs/Lows of aTyr Pharma Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.69 18.34 % 1.54 % 2.021.6817-May-2413-May-24
Two Week1.61 24.22 % 3.42 % 2.021.590117-May-2406-May-24
One Month1.59 25.79 % 5.60 % 2.021.5417-May-2402-May-24
Three Month2.02 0.990 % 5.95 % 2.151.5420-Mar-2402-May-24
Six Months1.14 75.44 % 17.48 % 2.151.1420-Mar-2411-Dec-23
One year2.52 20.63 % 27.52 % 2.61.080118-May-2313-Nov-23
Two year3.2 37.50 % 29.70 % 3.071.080104-Oct-2213-Nov-23
Five year6.5016 69.24 % 85.46 % 21.711.080112-Feb-2413-Nov-23


Technical View of aTyr Pharma Inc
RSI

74.11

Mild Bullish
MACD

0.0485

Bullish
ADX

22.95

Bullish
Super Trend

1.69

Mild Bullish
Williams %R

-4.17

Mild Bearish
CCI

211.50

Mild Bearish


EMA 5

1.89

Strong Bullish
EMA 15

1.77

Strong Bullish
EMA 50

1.74

Whipsaw
EMA 100

1.70

Bullish
SMA 100

1.72

Whipsaw
SMA 200

1.60

Whipsaw
SMA 5 / 20

1.87 / 1.69

Strong Bullish
SMA 15 / 50

1.72 / 1.76

Mild Bearish
SMA 50 / 200

1.76 / 1.60

Mild Bullish




Charts of aTyr Pharma Inc


Returns of aTyr Pharma Inc with Peers
Period / StockLIFEAKYAMCRBRANI
1 Week18.34%-33.18%-9.81%-17.27%
1 Mth25.79%-27.11%46.64%-33.50%
3 Mth-0.990%-52.18%-12.39%52.19%
6mth75.44%-34.18%-35.22%159.70%
1 Year-20.63%-53.43%-81.34%13.97%
2 Year-37.50%-68.44%-74.59%-54.61%
5 Years-69.24%--77.73%-97.55%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of aTyr Pharma Inc with Peers
Ratio / StockLIFEAKYAMCRBRANI
PE-512.96-1028.39-362.29-4.06
P/B282.71450.24-1033.123.63
ROA-42.90-39.74-23.70-45.72
ROE-55.09-129.540-178.56
Debt To Equity0.01461.46-2.412.34
Revenue10739.00 K
3.40 % 		91365.00 K
22.05 % 		127236 K
1685.02 % 		0
%
Net Income-43150.00 K
4.83 % 		-71396.00 K
1.07 % 		-141272.00 K
43.53 % 		-35658.00 K
16.58 %


Technicals of aTyr Pharma Inc with Peers
Technical / StockLIFEAKYAMCRBRANI-
ADX22.9532.4232.9125.78
CMF-0.066-0.1790.2290.108
MFI84.3437.0463.8054.97
RSI74.1127.3550.8240.99
MACD Abv SignalTrueFalseFalseFalse
Price Above 50 MATrueFalseTrueTrue-
Price Above 200 MATrueFalseFalseTrue-


About : aTyr Pharma Inc

Address : 10240 Sorrento Valley Road, San Diego, CA, United States, 92121
Tel : 858 731 8389
URL : https://www.atyrpharma.com
Code : LIFE, ISIN : US0021202025, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 07_May_2015
Employee Count : 56

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)